Lytus Technologies Holdings(LYT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LYT Lytus Technologies Holdings

Pre-Market Trading 01-10 06:16:02 EST

0.7496

-0.0704

-8.59%

盘前0.8000

+0.0504+6.72%

05:33 EST

High0.8100	Low0.7301	Vol797.43K
Open0.8100	D1 Closing0.8200	Amplitude9.74%
Mkt Cap17.74M	Tradable Cap16.80M	Total Shares23.66M
T/O603.10K	T/O Rate3.56%	Tradable Shares22.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LYT","market":"US","secType":"STK","nameCN":"Lytus Technologies Holdings","latestPrice":0.7496,"timestamp":1736370000000,"preClose":0.82,"halted":0,"volume":797431,"hourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.7496,"latestTime":"05:33 EST","volume":23,"amount":19.69000031,"timestamp":1736505187967},"delay":0,"floatShares":22415400,"shares":23659400,"eps":0.297329,"marketStatus":"Pre-Market Trading","change":-0.0704,"latestTime":"01-10 06:16:02 EST","open":0.81,"high":0.81,"low":0.7301,"amount":603102.2246785699,"amplitude":0.097439,"askPrice":0.8683,"askSize":100,"bidPrice":0.7358,"bidSize":40,"shortable":0,"etf":0,"ttmEps":0.297329,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736519400000},"marketStatusCode":1,"adr":0,"listingDate":1655265600000,"exchange":"NASDAQ","adjPreClose":0.7496,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.7496,"latestTime":"05:33 EST","volume":23,"amount":19.69000031,"timestamp":1736505187967},"postHourTrading":{"tag":"盘后","latestPrice":0.76,"preClose":0.7496,"latestTime":"19:55 EST","volume":14399,"amount":10810.2625,"timestamp":1736384113705},"volumeRatio":1.0308322423706107},"requestUrl":"/m/hq/s/LYT/wiki","defaultTab":"wiki","newsList":[{"id":"2502044715","title":"PureTech Health Gets US FDA Fast Track Designation for LYT-200 to Treat Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2502044715","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502044715?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:57","pubTimestamp":1736441856,"startTime":"0","endTime":"0","summary":"PureTech Health  said Thursday the US Food and Drug Administration has given fast track designation to LYT-200 to treat acute myeloid leukemia.The label was designed to expedite the assessment of drugs for serious diseases with unmet medical need, the company said.The regulator previously granted orphan drug designation to LYT-200 to treat acute myeloid leukemia, as well as a separate fast track designation to treat head and neck cancers, the company said.Price: 17.55, Change: -0.76, Percent Change: -4.15","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4108","PRTC","BK4567","IE00BYQQ9H92.USD","LYT","BK4588","BK4585","BK4104","IE00BFXG0V08.USD","IE00B5TLWC47.USD","BK4139","FAST"],"gpt_icon":0},{"id":"2502048551","title":"BRIEF-PureTech Health Says PRTC's LYT-200 Gets Fast Track Designation In AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2502048551","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502048551?lang=en_us&edition=fundamental","pubTime":"2025-01-09 22:34","pubTimestamp":1736433283,"startTime":"0","endTime":"0","summary":"Jan 9 (Reuters) - PureTech Health PLC   :   * PURETECH HEALTH PLC  - PRTC'S LYT-200 GETS FAST TRACK DESIGNATION IN AMLSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRTC","IE00BFXG0V08.USD","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","BK4567","BK4104","BK4585","FAST","LYT","BK4139","BK4108","BK4588"],"gpt_icon":0},{"id":"2502016348","title":"PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2502016348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502016348?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:15","pubTimestamp":1736424914,"startTime":"0","endTime":"0","summary":"PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-ga...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/puretech-announces-receipt-of-fda-fast-track-designation-for-lyt-200-in-aml?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/puretech-announces-receipt-of-fda-fast-track-designation-for-lyt-200-in-aml?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BFXG0V08.USD","BK4588","IE00BYQQ9H92.USD","LYT","BK4108","BK4567","IE00B5TLWC47.USD","BK4104","PRTC","FAST","BK4139"],"gpt_icon":0},{"id":"2502001102","title":"PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502001102","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502001102?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":"Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment. LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers. BOSTON, January 09, 2025----PureTech Health plc  , a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration  has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia . Fast Track designation is a process designed to streamline the development and accelerate the assessment of drugs that target serious conditions with unmet medical need.Phase 1/2 clinical trial evaluating LYT-200 as a monotherapy and in combination with venetoclax and hypomethylating agents in hematological malignancies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-receives-fda-fast-track-120000986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRTC","FAST","BK4139","BK4108","LYT"],"gpt_icon":0},{"id":"2494732804","title":"Lytus Technologies Files for Up to $75 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2494732804","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494732804?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:35","pubTimestamp":1735302950,"startTime":"0","endTime":"0","summary":"Lytus Technologies  filed a registration statement Friday covering the potential sale of up to $75 million in securities.The securities, which may be offered from time to time, consist of common shares, preferred shares, debt securities, warrants, rights and units.Shares of Lytus were down more than 2% in recent premarket activity Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LYT","BK4108"],"gpt_icon":0},{"id":"2494467801","title":"Corrected-Lytus Technologies Holdings Ptv Ltd Files for Mixed Shelf of up to $75 Mln (Adds '$' Symbol, Removes Extraneous Words) - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2494467801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494467801?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:10","pubTimestamp":1735301427,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nL8N3NS0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4108","LYT"],"gpt_icon":0},{"id":"2494014278","title":"BRIEF-Lytus Technologies Holdings Ptv Files For Mixed Shelf Of Up To $75 Mln-SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2494014278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494014278?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:10","pubTimestamp":1735301427,"startTime":"0","endTime":"0","summary":"BRIEF-Lytus Technologies Holdings Ptv Files For Mixed Shelf Of Up To $75 Mln-SEC FilingDec 27  - Lytus Technologies Holdings Ptv Ltd LYT.O:LYTUS TECHNOLOGIES HOLDINGS PTV LTD FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILINGSource text: [ID:]Further company coverage: LYT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nL8N3NS0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYT","BK4108"],"gpt_icon":0},{"id":"2494805249","title":"Lytus Technologies files $75M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2494805249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494805249?lang=en_us&edition=fundamental","pubTime":"2024-12-27 19:10","pubTimestamp":1735297807,"startTime":"0","endTime":"0","summary":"06:08 EST Lytus Technologies (LYT) files $75M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lytus-technologies-files-75m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lytus-technologies-files-75m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4108","LYT"],"gpt_icon":0},{"id":"2491663418","title":"NASDAQ-Listed LYTUS Appoints Visionary Leader Sai Guna Ranjan Puranam as COO (Lytus Healthcare) and Group CTO (Lytus Technologies) to Revolutionize Healthcare and Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2491663418","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491663418?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:22","pubTimestamp":1734344520,"startTime":"0","endTime":"0","summary":"MUMBAI, India, Dec. 16, 2024 /PRNewswire/ -- Lytus Technologies , a forward-thinking platform services entity renowned for its innovation-driven business model, today announced the appointment of Sai Guna Ranjan Puranamas Chief Operating Officer  and Group Chief Technology Officer . In these pivotal roles, Sai will lead the operational and technological transformation at Lytus, positioning the company to set new benchmarks in healthcare and technology.Lytus Technologies Holdings is a NASDAQ-listed platform services entity that builds and invests in businesses driving next-generation technology solutions. With a focus on digital streaming, healthtech, fintech, AI, cybersecurity, and more, Lytus operates across India and various international markets, serving a growing base of 4 million customers","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sgS62_ISX1_MqyAbXRIuJw--~B/aD00MDA7dz0zNjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f665c8849368d1612e5cafeca0b49edf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sgS62_ISX1_MqyAbXRIuJw--~B/aD00MDA7dz0zNjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f665c8849368d1612e5cafeca0b49edf"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nasdaq-listed-lytus-appoints-visionary-102200341.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nasdaq-listed-lytus-appoints-visionary-102200341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1992135472.HKD","BK4160",".IXIC","LYT","BK4588","LU2272731600.USD","NDAQ","LU1992135399.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4108","LU2095319765.USD","IE00BGHQF748.EUR","BK4137","CTO","BK4198","COO","BK4585","IE00B3QW5Z07.USD","HCSG","IE00BKPKM429.USD","GB00BDT5M118.USD","LU2211815571.USD","LU2272731782.SGD"],"gpt_icon":0},{"id":"2491630242","title":"PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2491630242","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491630242?lang=en_us&edition=fundamental","pubTime":"2024-12-16 15:00","pubTimestamp":1734332400,"startTime":"0","endTime":"0","summary":"Dose-ranging trial evaluated deupirfenidone 550 mg three times a day   and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response. Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL. Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo. Deupirfenidone was generally well-tolerated with a favorable adverse event profile at both doses studied. Data support continued development of deupirfenidone and highlight its potential to serve as a new standard-of-care treatment for IPF. The trial achieved its primary endpoint based on the prespecified Bayesian analysis, with a 98.5% posterior pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/J5fYJxFE4pyssR9xDNbqvQ--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/81da310f23c30be118b4be1c66cbfe98","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/J5fYJxFE4pyssR9xDNbqvQ--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/81da310f23c30be118b4be1c66cbfe98"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-deupirfenidone-lyt-100-slowed-070000163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ58947870.SGD","IE0034224299.USD","SG9999014484.SGD","PRTC","BK4585","LU0261945553.USD","SG9999006266.SGD","BK4535","SG9999013486.USD","SG9999001135.SGD","BK4139","SG9999014492.USD","LU0737861269.HKD","BK4503","SG9999002620.SGD","BK4551","BK4085","BK4554","SG9999004360.SGD","LU0210637038.USD","SG9999002406.SGD","LU1242518931.SGD","BK4108","LU2045819591.USD","BK4566","LYT","BK4548","LU1242518857.USD","LU2125910500.SGD","LU0532188223.SGD","SG9999002604.SGD","SG9999005177.SGD","SG9999013460.SGD","SG9999013478.USD","SG9999002679.SGD","FVC","BK4581","BK4588","BK4156","LU0048573645.USD","LU0251143029.SGD","SG9999002414.USD","LU0979878070.USD"],"gpt_icon":1},{"id":"2490374220","title":"PureTech Health presents data from dose escalation phase of LYT-200 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490374220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490374220?lang=en_us&edition=fundamental","pubTime":"2024-12-09 18:30","pubTimestamp":1733740251,"startTime":"0","endTime":"0","summary":"PureTech Health (PRTC) presented data from the dose escalation phase of its ongoing Phase 1b trial evaluating LYT-200, an anti-galectin-9 monoclona...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-data-from-dose-escalation-phase-of-lyt-200-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-data-from-dose-escalation-phase-of-lyt-200-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRTC","BK4108","LYT"],"gpt_icon":0},{"id":"2490744545","title":"PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490744545","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490744545?lang=en_us&edition=fundamental","pubTime":"2024-12-09 15:00","pubTimestamp":1733727600,"startTime":"0","endTime":"0","summary":"LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents. LYT-200 demonstrates clinical benefit as a single agent, with two partial responses and 59% of evaluable patients achieving stable disease or better. In combination, two complete responses were seen and 80% of evaluable patients achieved stable disease or better1. Data support LYT-200 as a potential first-line treatment for AML/MDS patients. BOSTON, December 09, 2024----PureTech Health plc  , a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented data from the dose escalation phase of its ongoing Phase 1b trial evaluating LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, in patients with relapsed or refractory acute myeloid leukemia  and myelodysplastic syndromes  at the 2024 American Society of Hematology  Annual Meeting in San Diego, California.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iw4R7F7Q3OHMxE.4UmS_Nw--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/3959d7cd9ca11eafab490c83249d420d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iw4R7F7Q3OHMxE.4UmS_Nw--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/3959d7cd9ca11eafab490c83249d420d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-presents-data-lyt-200-070000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4108","LU2463526074.USD","PRTC","HMA","ASH","LYT","BK4109","BK4139"],"gpt_icon":0},{"id":"2485043906","title":"Positive Outlook on PureTech Health’s LYT-100 Amid Potential Breakthrough in IPF Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2485043906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485043906?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:15","pubTimestamp":1732169731,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on PureTech Health (PRTC – Research Report) on November 19 and set a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-puretech-healths-lyt-100-amid-potential-breakthrough-in-ipf-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-puretech-healths-lyt-100-amid-potential-breakthrough-in-ipf-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4108","LYT"],"gpt_icon":0},{"id":"2479081101","title":"Potential Upside For Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) Not Without Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2479081101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479081101?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:19","pubTimestamp":1730373571,"startTime":"0","endTime":"0","summary":"With a price-to-sales (or \"P/S\") ratio of 0.2x Lytus Technologies Holdings PTV. Ltd. ( NASDAQ:LYT ) may be sending...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4313000-choice2-main-header/1585186808281","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4313000-choice2-main-header/1585186808281"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nasdaq-lyt/lytus-technologies-holdings-ptv/news/potential-upside-for-lytus-technologies-holdings-ptv-ltd-nas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ","QID","BK4585","QLD","PSQ","MNQmain","LYT","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","BK4108","TQQQ","BK4112","NQmain","LU2210150020.SGD"],"gpt_icon":1},{"id":"2474214103","title":"PureTech Health presents LYT-100 data at CHEST 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2474214103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474214103?lang=en_us&edition=fundamental","pubTime":"2024-10-09 17:35","pubTimestamp":1728466515,"startTime":"0","endTime":"0","summary":"PureTech Health presented two oral presentations and one poster supporting its clinical and patient engagement strategies related to LYT-100 for th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-lyt-100-data-at-chest-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/puretech-health-presents-lyt-100-data-at-chest-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4108","LYT"],"gpt_icon":0},{"id":"2474936222","title":"PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2474936222","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474936222?lang=en_us&edition=fundamental","pubTime":"2024-10-09 14:00","pubTimestamp":1728453600,"startTime":"0","endTime":"0","summary":"IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF. Clinical abstract reviews the ability of Bayesian analysis to maximize statistical power and reduce the number of patients on placebo in Phase 2b ELEVATE IPF trial of LYT-100. Topline data from the Phase 2b ELEVATE IPF trial of LYT-100 expected by the end of 2024. Beyond this, PureTech’s research revealed commonalities and differences in the patient experience for those receiving care at interstitial lung disease  centers  versus community pulmonary practices  . When asked about their top resources for IPF information, nearly all people in both care settings listed their pulmonologist as their primary source, and the majority in each were very satisfied with their communications about their IPF diagnosis. Antifibrotic treatment rates at ILD centers and CPPs were similar, but differences existed in perceived communication around antifibrot","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NIcN_B6onVdkfR5MrAtpig--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a93bdb2b08af2ad9bb2e66e5ca32d64e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NIcN_B6onVdkfR5MrAtpig--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a93bdb2b08af2ad9bb2e66e5ca32d64e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-presents-research-highlighting-burden-060000845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4108","BK4139","PRTC","FVC","LYT"],"gpt_icon":0},{"id":"2460033467","title":"US Markets Flat in Pre-Bell Following Biggest Weekly Gain of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2460033467","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460033467?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:28","pubTimestamp":1724070511,"startTime":"0","endTime":"0","summary":"US stock futures were treading water in Monday's premarket session following the S&P 500's biggest weekly gain of the year, and as investors look ahead to Friday's speech from Federal Reserve Chairman","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","LQDA","BK4583","IE00B19Z4B17.USD","RILY","TNXP","IE00B7SZL793.SGD","BK4108","APDN","IE00B66KJ199.SGD","SPRC","BK4007","BK4127","LYT","BK4139","IE0031619046.USD"],"gpt_icon":1},{"id":"2460033042","title":"US Markets Flat in Pre-Bell Following Biggest Weekly Gain of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2460033042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460033042?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:28","pubTimestamp":1724070511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["IE00BKPKM429.USD","US5Y.BOND","TQQQ","DDM","BK4127","RILY","SPRC","US3Y.BOND",".DJI",".SPX","SDOW","DJX","US10Y.BOND","RILYI","APDN","DOG","BK4139",".IXIC","US6M.BOND","US7Y.BOND","US30Y.BOND","BK4532","NQmain","US2Y.BOND","DNA","LU2210150020.SGD","SPY","LYT","PSQ","LU2210149790.SGD","NDAQ","VOO","IE0031619046.USD","BK4585","LQDA","BK4108","LU2095319765.USD","QID","DXD","QLD","UTHR","MNQmain","QQQ","TNXP","POWL","SQQQ","UDOW","BK4109","US12M.BOND","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2457045572","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2457045572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457045572?lang=en_us&edition=fundamental","pubTime":"2024-08-06 19:44","pubTimestamp":1722944692,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4089","BK4535","BK4139","BK4108","BK4539","BK4554","TENX","RXST","LYT","BK4588","LUMN","VSEE","BK4167","BK4198","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lytuscorp.com","stockEarnings":[{"period":"1week","weight":-0.1066},{"period":"1month","weight":-0.4607},{"period":"3month","weight":-0.5741},{"period":"6month","weight":-0.6654},{"period":"1year","weight":-0.8767},{"period":"ytd","weight":-0.1066}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lytus Technologies Holdings PTV. Ltd. operates as a platform services company in India. It operates in two segments, Cable Services and Telemedicine Services. The company engages in the distribution of linear content streaming/telecasting services; and development of telemedicine and fintech products. Lytus Technologies Holdings PTV. Ltd. was incorporated in 2020 and is based in Mumbai, India.","exchange":"NASDAQ","name":"Lytus Technologies Holdings","nameEN":"Lytus Technologies Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lytus Technologies Holdings(LYT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lytus Technologies Holdings(LYT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lytus Technologies Holdings,LYT,Lytus Technologies Holdings股票,Lytus Technologies Holdings股票老虎,Lytus Technologies Holdings股票老虎国际,Lytus Technologies Holdings行情,Lytus Technologies Holdings股票行情,Lytus Technologies Holdings股价,Lytus Technologies Holdings股市,Lytus Technologies Holdings股票价格,Lytus Technologies Holdings股票交易,Lytus Technologies Holdings股票购买,Lytus Technologies Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lytus Technologies Holdings(LYT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lytus Technologies Holdings(LYT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction